The Role of Fucoxanthin in Non-Alcoholic Fatty Liver Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 May 13

PMID 37175909

Authors

Jessica Winarto

Dae-Geun Song

Cheol-Ho Pan

Affiliations

Soon will be listed here.

Abstract

Chronic liver disease (CLD) has emerged as a leading cause of human deaths. It caused 1.32 million deaths in 2017, which affected men more than women by a two-to-one ratio. There are various causes of CLD, including obesity, excessive alcohol consumption, and viral infection. Among them, non-alcoholic fatty liver disease (NAFLD), one of obesity-induced liver diseases, is the major cause, representing the cause of more than 50% of cases. Fucoxanthin, a carotenoid mainly found in brown seaweed, exhibits various biological activities against NAFLD. Its role in NAFLD appears in several mechanisms, such as inducing thermogenesis in mitochondrial homeostasis, altering lipid metabolism, and promoting anti-inflammatory and anti-oxidant activities. The corresponding altered signaling pathways are the β3-adorenarine receptor (β3Ad), proliferator-activated receptor gamma coactivator (PGC-1), adenosine monophosphate-activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), sterol regulatory element binding protein (SREBP), nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), protein kinase B (AKT), SMAD2/3, and P13K/Akt pathways. Fucoxanthin also exhibits anti-fibrogenic activity that prevents non-alcoholic steatohepatitis (NASH) development.

Citing Articles

Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs.

Wan X, Ma J, Bai H, Hu X, Ma Y, Zhao M Biomolecules. 2025; 15(1).

PMID: 39858534 PMC: 11764138. DOI: 10.3390/biom15010140.

Fucoxanthin Inhibits the Proliferation and Metastasis of Human Pharyngeal Squamous Cell Carcinoma by Regulating the PI3K/Akt/mTOR Signaling Pathway.

Du H, Jiang J, Wu S, Shi Y, Liu H, Hua Z Molecules. 2024; 29(15).

PMID: 39125009 PMC: 11314479. DOI: 10.3390/molecules29153603.

Lead-induced liver fibrosis and inflammation in mice by the AMPK/MAPKs/NF-κB and STAT3/TGF-β1/Smad2/3 pathways: the role of Isochlorogenic acid a.

Guo J, Li H, Cheng C, Shi J, Ruan H, Li J Toxicol Res (Camb). 2024; 13(3):tfae072.

PMID: 38737339 PMC: 11081073. DOI: 10.1093/toxres/tfae072.

Genetically determined circulating micronutrients and the risk of nonalcoholic fatty liver disease.

Liu K, Chen Y, Chen J, Chen W, Sun X, Mao Y Sci Rep. 2024; 14(1):1105.

PMID: 38212362 PMC: 10784479. DOI: 10.1038/s41598-024-51609-3.

Fucoxanthin Enhances the Antifibrotic Potential of Placenta-derived Mesenchymal Stem Cells in a CCl4-induced Mouse Model of Liver.

Slautin V, Konyshev K, Gavrilov I, Beresneva O, Maklakova I, Grebnev D Curr Stem Cell Res Ther. 2024; 19(11):1484-1496.

PMID: 38204245 DOI: 10.2174/011574888X279940231206100902.

References

Muradian K, Vaiserman A, Min K, Fraifeld V . Fucoxanthin and lipid metabolism: A minireview. Nutr Metab Cardiovasc Dis. 2015; 25(10):891-7. DOI: 10.1016/j.numecd.2015.05.010. View

Kim M, Bae M, Lee Y, Kang H, Hu S, Pham T . Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity. Nutrients. 2022; 14(11). PMC: 9183127. DOI: 10.3390/nu14112280. View

Polyzos S, Kountouras J, Mantzoros C . Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2018; 92:82-97. DOI: 10.1016/j.metabol.2018.11.014. View

Kim Y, Lee E, Shin K, Kim M, Pewzner-Jung Y, Lee Y . Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases. Exp Mol Med. 2019; 51(11):1-16. PMC: 6825147. DOI: 10.1038/s12276-019-0340-1. View

Yuan Y, Ma M, Zhang S . Recent advances in delivery systems of fucoxanthin. Food Chem. 2022; 404(Pt B):134685. DOI: 10.1016/j.foodchem.2022.134685. View

Soriano E, Fernandez I . Allenes and computational chemistry: from bonding situations to reaction mechanisms. Chem Soc Rev. 2014; 43(9):3041-105. DOI: 10.1039/c3cs60457h. View

Kang S, Ko H, Shin H, Kim H, Hong Y, Lee N . Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem Biophys Res Commun. 2011; 409(4):769-74. DOI: 10.1016/j.bbrc.2011.05.086. View

Wu L, Liu Y, Zhao Y, Li M, Guo L . Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Free Radic Biol Med. 2020; 153:140-158. DOI: 10.1016/j.freeradbiomed.2020.04.009. View

Meng X, Guo J, Fang W, Dou L, Li M, Huang X . Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1. J Biol Chem. 2016; 291(20):10625-34. PMC: 4865911. DOI: 10.1074/jbc.M116.713768. View

10.

Kang S, Shin H, Kim H, Yoon S, Kang S, Kim J . Petalonia binghamiae extract and its constituent fucoxanthin ameliorate high-fat diet-induced obesity by activating AMP-activated protein kinase. J Agric Food Chem. 2012; 60(13):3389-95. DOI: 10.1021/jf2047652. View

11.

Das S, Hashimoto T, Kanazawa K . Growth inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is associated with down-regulation of cyclin D. Biochim Biophys Acta. 2008; 1780(4):743-9. DOI: 10.1016/j.bbagen.2008.01.003. View

12.

Gruzman A, Babai G, Sasson S . Adenosine Monophosphate-Activated Protein Kinase (AMPK) as a New Target for Antidiabetic Drugs: A Review on Metabolic, Pharmacological and Chemical Considerations. Rev Diabet Stud. 2009; 6(1):13-36. PMC: 2712919. DOI: 10.1900/RDS.2009.6.13. View

13.

Seale P . Transcriptional control of brown adipocyte development and thermogenesis. Int J Obes (Lond). 2010; 34 Suppl 1:S17-22. DOI: 10.1038/ijo.2010.178. View

14.

Divakaruni A, Brand M . The regulation and physiology of mitochondrial proton leak. Physiology (Bethesda). 2011; 26(3):192-205. DOI: 10.1152/physiol.00046.2010. View

15.

Kersten S, Mandard S, Tan N, Escher P, Metzger D, Chambon P . Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem. 2000; 275(37):28488-93. DOI: 10.1074/jbc.M004029200. View

16.

Beppu F, Niwano Y, Tsukui T, Hosokawa M, Miyashita K . Single and repeated oral dose toxicity study of fucoxanthin (FX), a marine carotenoid, in mice. J Toxicol Sci. 2009; 34(5):501-10. DOI: 10.2131/jts.34.501. View

17.

Brieger K, Schiavone S, Miller Jr F, Krause K . Reactive oxygen species: from health to disease. Swiss Med Wkly. 2012; 142:w13659. DOI: 10.4414/smw.2012.13659. View

18.

Liu W, Cao H, Ye C, Chang C, Lu M, Jing Y . Hepatic miR-378 targets p110α and controls glucose and lipid homeostasis by modulating hepatic insulin signalling. Nat Commun. 2014; 5:5684. DOI: 10.1038/ncomms6684. View

19.

Tavares R, Maria-Engler S, Colepicolo P, Debonsi H, Schafer-Korting M, Marx U . Skin Irritation Testing beyond Tissue Viability: Fucoxanthin Effects on Inflammation, Homeostasis, and Metabolism. Pharmaceutics. 2020; 12(2). PMC: 7076544. DOI: 10.3390/pharmaceutics12020136. View

20.

Zhu J, Li H, Xu Y, Wang D . Construction of Fucoxanthin Vector Based on Binding of Whey Protein Isolate and Its Subsequent Complex Coacervation with Lysozyme. J Agric Food Chem. 2019; 67(10):2980-2990. DOI: 10.1021/acs.jafc.8b06679. View